DPAM
TEVA icon

Degroof Petercam Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Degroof Petercam Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$265K Sell
19,100
-5,100
-21% -$64.3K ﹤0.01% 574
2023
Q4 		$253K Buy
+24,200
New +$226K ﹤0.01% 581

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Degroof Petercam Asset Management's TEVA Position: Q1 2024 in Review

Degroof Petercam Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 21% in Q1 2024, selling an estimated $64.3K and leaving 19,100 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #574.

Degroof Petercam Asset Management first reported a position in TEVA in Q4 2023 and has held it in 2 quarters since. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Degroof Petercam Asset Management held 19,100 shares of Teva Pharmaceuticals worth $265K as of Q1 2024.
  • Degroof Petercam Asset Management sold 5,100 Teva Pharmaceuticals shares in Q1 2024, an estimated $64.3K.
  • Teva Pharmaceuticals made up ﹤0.01% of Degroof Petercam Asset Management's portfolio in Q1 2024, its #574 holding.
  • Degroof Petercam Asset Management first reported a position in Teva Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Degroof Petercam Asset Management's 13F filing for Q1 2024, filed 13 May 2024.